Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
Mainz Biomed (NASDAQ:MYNZ) announced it will attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) from 14–15 November 2025 in Bad Kreuznach, Germany.
The company plans to present its flagship diagnostic ColoAlert® and discuss upcoming solutions for early detection of colorectal and other cancers, engage with gastroenterology key opinion leaders, and explore clinical collaborations. Attendees are invited to visit Mainz Biomed's booth to learn about offering ColoAlert to patients.
For more information, investors and physicians are directed to the company investor site at mainzbiomed.com/investors/ and the company's social channels.
Mainz Biomed (NASDAQ:MYNZ) ha annunciato che parteciperà al 38° Incontro Annuale del Gruppo di Lavoro Gastroenterologico della Renania-Palatinato (GARPS) dal 14 al 15 novembre 2025 a Bad Kreuznach, Germania.
L'azienda prevede di presentare il suo diagnostico di punta ColoAlert® e discutere soluzioni imminenti per l'individuazione precoce del cancro del colon-retto e di altri tumori, coinvolgere i principali opinioni leader della gastroenterologia ed esplorare collaborazioni cliniche. I partecipanti sono invitati a visitare lo stand di Mainz Biomed per conoscere l'offerta ColoAlert ai pazienti.
Per ulteriori informazioni, investitori e medici sono indirizzati al sito investitori dell'azienda all'indirizzo mainzbiomed.com/investors/ e ai canali social dell'azienda.
Mainz Biomed (NASDAQ:MYNZ) anunció que asistirá a la 38ª Reunión Anual del Grupo de Trabajo de Gastroenterología de Renania-Palatinado (GARPS) del 14 al 15 de noviembre de 2025 en Bad Kreuznach, Alemania.
La empresa planea presentar su diagnóstico insignia ColoAlert® y discutir soluciones próximas para la detección temprana de cáncer colorrectal y otros cánceres, interactuar con líderes de opinión clave en gastroenterología y explorar colaboraciones clínicas. Se invita a los asistentes a visitar el stand de Mainz Biomed para conocer la oferta de ColoAlert a los pacientes.
Para más información, los inversores y los médicos deben dirigirse al sitio de inversores de la empresa en mainzbiomed.com/investors/ y a los canales sociales de la empresa.
Mainz Biomed(NASDAQ:MYNZ) 는 2025년 11월 14일부터 15일까지 독일 바드 크로인크나흐에서 열리는 38회 연례 Rhineland-Palatinate 소화기학 워킹그룹 GARPS 회의에 참석한다고 발표했습니다.
회사는 자사의 주력 진단기 ColoAlert®를 선보이고 대장암 및 기타 암의 조기 발견을 위한 향후 솔루션을 논의하며, 위장병학 핵심 의견 리더들과 교류하고 임상 협력을 탐색할 계획입니다. 참석자들은 ColoAlert를 환자들에게 제공하는 것에 대해 알아보기 위해 Mainz Biomed의 부스를 방문하도록 초대받습니다.
추가 정보는 투자자 및 의사들을 위해 회사의 투자자 사이트 mainzbiomed.com/investors/과 회사의 소셜 채널에서 안내됩니다.
Mainz Biomed (NASDAQ:MYNZ) a annoncé qu'il assistera à la 38e Réunion Annuelle du Groupe de Travail de Gastro-entérologie de la Rhénanie-Palatinat (GARPS) du 14 au 15 novembre 2025 à Bad Kreuznach, Allemagne.
L'entreprise prévoit de présenter son diagnostic phare ColoAlert® et de discuter des solutions à venir pour le dépistage précoce du cancer colorectal et d'autres cancers, d'engager les leaders d'opinion clés en gastro-entérologie et d'explorer des collaborations cliniques. Les participants sont invités à visiter le stand de Mainz Biomed pour en savoir plus sur l'offre ColoAlert aux patients.
Pour plus d'informations, les investisseurs et les médecins sont dirigés vers le site des investisseurs de l'entreprise à mainzbiomed.com/investors/ et les canaux sociaux de l'entreprise.
Mainz Biomed (NASDAQ:MYNZ) kündigte an, dass es an der 38. Jahresversammlung der Arbeitsgruppe Gastroenterologie Rheinland-Pfalz (GARPS) vom 14.–15. November 2025 in Bad Kreuznach, Deutschland, teilnehmen wird.
Das Unternehmen plant, seinen führenden diagnostischen Tests ColoAlert® vorzustellen und kommende Lösungen für die frühzeitige Erkennung von kolorektalen Krebsarten und anderen Krebsarten zu diskutieren, mit führenden Meinungsbildnern der Gastroenterologie in Kontakt zu treten und klinische Kooperationen zu erkunden. Besucherinnen und Besucher sind eingeladen, den Messestand von Mainz Biomed zu besuchen, um zu erfahren, wie ColoAlert Patienten angeboten wird.
Für weitere Informationen wenden sich Investoren und Ärzte bitte an die Investorenseite des Unternehmens unter mainzbiomed.com/investors/ sowie an die Social-Mate-Kanäle des Unternehmens.
أعلنت شركة Mainz Biomed (NASDAQ:MYNZ) أنها ستشارك في الاجتماع السنوي الثامن والثلاثين لمجموعة العمل المعنية بالجهاز الهضمي في راينلاند-فالتس (GARPS) من 14 إلى 15 نوفمبر 2025 في باد كرويتسناخ، ألمانيا.
تخطط الشركة لعرض تشخيصها الرائد ColoAlert® ومناقشة الحلول القادمة للكشف المبكر عن سرطان القولون وغيره من السرطانات، والتفاعل مع قادة الرأي الرئيسيين في علم أمراض الجهاز الهضمي واستكشاف التعاونات السريرية. يُدعى الحاضرون لزيارة جناح Mainz Biomed للاطلاع على تقديم ColoAlert للمرضى.
للمزيد من المعلومات، يتم توجيه المستثمرين والأطباء إلى موقع الشركة للمستثمرين على mainzbiomed.com/investors/ والقنوات الاجتماعية للشركة.
- None.
- None.
BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) taking place from 14–15 November, 2025, in Bad Kreuznach, Germany.
The annual GARPS conference brings together clinical and scientific expertise from across the Rhineland-Palatinate region, serving as an important platform for knowledge exchange in the fields of gastroenterology and hepatology. This form of regional congress promotes valuable dialogue between universities, hospitals, private practices, and representatives of the research and diagnostics industry.
Mainz Biomed will use the opportunity to further strengthen relationships with key opinion leaders in gastroenterology, exchange insights on the future of cancer prevention, and present its current flagship product, ColoAlert®, and further upcoming diagnostic solutions designed to enhance early detection of colorectal and other cancers.
Attendees are invited to visit the booth to learn more about the critical significance of early colorectal cancer detection and to explore potential collaborations with physicians and how to offer ColoAlert to their patients.
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
When and where will Mainz Biomed (MYNZ) attend the GARPS meeting in 2025?
What will Mainz Biomed (MYNZ) present at the GARPS 2025 meeting?
Can physicians meet Mainz Biomed (MYNZ) at the GARPS conference to discuss ColoAlert?
Where can investors find more information about Mainz Biomed (MYNZ) related to the GARPS appearance?
Will Mainz Biomed (MYNZ) be discussing clinical or research collaborations at GARPS 2025?
